Committee Recommends Accutane “iPLEDGE” Tweaks, But Concerns Linger

FDA should modify the isotretinoin "iPLEDGE" risk management program to increase patient accessibility to Roche's Accutane and generic versions of the treatment for severe recalcitrant nodular acne, an advisory committee unanimously recommended Aug. 1